Oral contraceptives and thromboembolic disease. I. Prospective and retrospective studies.
D002170:Canada; D003276:Contraceptives, Oral / Q000009:adverse effects; D004739:England; D005260:Female; D006801:Humans; D008656:Mestranol / Q000008:administration & dosage / Q000009:adverse effects; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects; D009641:Norethynodrel / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000453:epidemiology; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000453:epidemiology; D011655:Pulmonary Embolism / Q000453:epidemiology; D012189:Retrospective Studies; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology; D014481:United States; D014852:Wales
D003276:Contraceptives, Oral; D009641:Norethynodrel; D008656:Mestranol; D009640:Norethindrone